Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine

Anti-Cancer Drugs

Volumn 14, Issue 8, 2003, Pages 665-668

  Rabinowits, Guilherme ^a   Herchenhorn, Daniel ^a,c   Rabinowits, Milton ^a   Weatge, Daniel ^b   Torres, Wilhermo ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Univ Federal do Rio de Janeiro ^*  (Brazil)

Author keywords

Gefitinib; Non small cell lung cancer; Pulmonary toxicity

Indexed keywords

AMIODARONE; ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DEXAMETHASONE; DRUG DERIVATIVE; GEFITINIB; GEMCITABINE; GRANISETRON; NITROPRUSSIDE SODIUM; PAMIDRONIC ACID; QUINAZOLINE DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; STEROID; ZOLEDRONIC ACID;

AGED; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BREATHING EXERCISE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CORONARY CARE UNIT; DISEASE SEVERITY; DISORIENTATION; DRUG EFFECT; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEMODYNAMIC MONITORING; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; IATROGENIC DISEASE; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG; LUNG BIOPSY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LUNG TUMOR; LYMPHADENOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PREMEDICATION; PRIORITY JOURNAL; RADIOGRAPHY; RESPIRATORY DISTRESS SYNDROME; RETICULOCYTOSIS; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA; TOMOGRAPHY; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VISUAL DISORDER;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LUNG; LUNG NEOPLASMS; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0142029623     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200309000-00014     Document Type: Article

References (14)

1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
2. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137-139.
3. Ochs JS. AstraZeneca Pharmaceuticals. Personal communication.
4. Twombly R. Cancer spectrum: despite concerns, FDA panel backs EGFR inhibitor. J Natl Cancer Inst 2002; 94:1596-1597.
5. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, et al. A phase III clinical trial of ZD1839 (Iressa®) in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced non-small cell lung cancer. Ann Oncol 2002; 13:4.
6. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, et al. ZD1839 (Iressa®) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer: results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13:468.
7. Rosado MF, Kett DH, Schein RMH, Baraona FJ, Sridhar KS. Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 2002; 25:31-33.
8. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002; 25:96-100.
9. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 2001; 12:1651-1652.
10. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000; 24:977-980.
11. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998; 114:1779-1781.
12. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002; 40:E16
13. Cooper JA, Zitnik R, Matthay RA. Mechanisms of drug-induced pulmonary disease. Ann Rev Med 1988; 39:395-404.
14. Martin II W, Rosenow III EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 1). Chest 1988; 93:1067-1075.